📌 Key Takeaways
- Topic: What Is Silicon Dioxide? Simple Definition, Formula and Everyday Examples
- Keywords: Covia silica
- Published: 2026-11-20 08:29:50
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Denka Spherical Silica: Product Overview, Specifications and Alternatives
- What Is Silane Treated Silica? How Silane Modification Improves Dispersion and Performance
- 29. Porrang S., Davaran S., Rahemi N., Allahyari S., Mostafavi E. How Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature. Int. J. Nanomed. 2022;17:1803-1827. doi: 10.2147/IJN.S353349. [ DOI ] [ PMC free piece ] [ PubMed ] [ Google Scholar ]
- What Is an Antiblock Agent for Film? How Silica Prevents Film Blocking
- MSNs are also appropriate for pulmonary drug delivery. Inhalation is an attractive route of administration since the application is non-invasive and patient-friendly [ 18 ]. However, the rapid mucociliary clearance and the mucus hurdle complicate the intake of the API and are obstacles to be overcome [ 18, 25 ]. The mesoporous drug delivery systems may be really helpful in the treatment of lung diseases, as they can passively accumulate in the alveoli [ 25, 56, 72 ]. The passive accumulation is due to their small size, while the sizable surface area, high vascularity, and vascular permeability of the lungs enhance the process [ 56 ]. Furthermore, targeted treatment of tumors or inflamed cells can also be implemented with the functionalization of their surface [ 56, 72 ]. MSNs are typically delivered to the lungs in powder form with dry powder inhalers or suspended in liquid droplets with a nebulizer [ 56 ].
- Silica 99.99% (4N): Specifications, Impurity Limits and Applications
- 7.2. Granules/Pellets
- Silica Powder Price: What Determines Cost and Typical Price Ranges
- Associated Data
Tosoh Silica: Product Range, Applications and Key Grades
What is silica (SiO₂)?
microsilica Table 4.
What is the difference between fumed silica and precipitated silica?
Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
What drives silica raw material prices?
silicon dioxide formula If you're looking to eat DE for the health benefits, we suggest starting with a single teaspoon a day. Simply mix it with a glass of water, juice or a smoothie. After 1 -2 weeks you can build up to a tablespoon a day if you want to grow the effects. Taking DE is generally more effective when done separately from other foods. When taken with food, the absorptive properties of DE are used to take in the nutrients of the food, rather than any toxins in your body. This lessens the effect of both the diatomaceous earth and your meal. The same is true of medications. If you are taking regular medications, we would inspire you to consult with your healthcare provider before taking DE.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.